The effectiveness of the inclusion of hyperbaric oxygenation in the complex therapy of patients with COVID-19: retrospective study

Cover Page

Cite item

Full Text

Abstract

INTRODUCTION: The pandemic of novel coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus has forced physicians to reconsider traditional approaches to the treatment of patients with viral pneumonia and acute respiratory distress syndrome, when normobaric oxygenation methods were ineffective. The way out of this situation was the inclusion of hyperbaric oxygenation in the complex therapy of patients with COVID-19, as a recognized means of eliminating any form of oxygen debt due to more efficient delivery of oxygen to organs and tissues. OBJECTIVE: To evaluate the effectiveness of hyperbaric oxygenation in the complex therapy of patients with a novel coronavirus infection with severe lung damage (more than 50%). MATERIALS AND METHODS: We examined 75 patients with the diagnosis «Coronavirus infection caused by the virus SARS-CoV-2» (64 patients with CT-3, 11 patients with CT-4), 50 of whom were prescribed a course of hyperbaric oxygen therapy (HBOT). The procedures were carried out in a Sechrist 2800 resuscitation pressure chamber (USA) at 1.4–1.6 ATA for no more than 60 minutes. Before and after each HBOT session, subjective indicators of the patients’ condition were assessed and blood oxygen saturation was measured. In addition, the dynamics of the level of leukocytes, platelets, ALT, AST and C-reactive protein were evaluated. In order to analyze oxygen support, the type (low-flow oxygen therapy, high-flow oxygen therapy) and daily oxygen consumption were recorded.

RESULTS: The inclusion of hyperbaric oxygenation in the complex therapy of patients with a novel coronavirus infection led to a significant increase in the level of SpO2 by the 7th day in the study group to 92% (89; 94) vs. 88% (87; 92) in the control group (p=0.011), and by 14th day to 96% (95; 97) vs. 95% (90; 96) (p<0.001). This circumstance led to a significant decrease in the number of patients requiring additional oxygen support, which was 94% in the study group and 100% in the control group by the 7th day, and 16% in the study group and 44% in the control group by the 14th day. In particular, the number of patients requiring high-flow oxygen therapy in the study group decreased from 34% on the 5th day to 2% on the 14th day, while in the control group over the same period there was a decrease from 60% to 32%. When analyzing the volumetric oxygen consumption in the study group, even taking into account the oxygen consumption for hyperbaric oxygenation, a decrease in the average daily oxygen consumption was recorded from 13.9 L/min on the 5th day to 9.3 L/min on the 14th day, while in the control group for the same period from 17.2 L/min to 14.5 L/min. The length of stay of patients in the intensive care unit in the study group was 10 (8; 12) vs. 13 (11; 23) bed-days (p=0.002) in the control group, and the total length of hospitalization was 16 (13.3; 20) vs. 21 (19; 29) bed-days (p><0.001) in the study and control groups, respectively. DISCUSSION: The early inclusion of hyperbaric oxygen therapy in the complex therapy of patients with a new coronavirus infection led to a significant increase in the level of SpO2 starting from the 7th day. This circumstance led to a significant decrease in number of patients requiring additional oxygen support in the study group compared to the control. This, in turn, affected the reduction in volumetric oxygen consumption in the study group, even taking into account the oxygen consumption on hyperbaric oxygenation. In addition, in the study group, positive dynamics according to CT data, a more rapid decrease in the level of C-reactive protein, were more often recorded. All these observations indicate a more rapid normalization of the state of the body due to the elimination of hypoxia, a decrease in the inflammatory response and restoration of lung function in patients who underwent hyperbaric oxygen therapy. CONCLUSION: The inclusion of HBO in the complex therapy of patients with a new coronavirus infection with severe lung damage (more than 50%) allows to stabilize the condition in a short time due to a more intensive decrease in the degree of lung damage according to CT data, early refusal of additional oxygen support, improvement of the psycho-emotional state, which in generally leads to a reduction in the length of stay of patients both in the ICU and in the hospital department.>< 0.001). This circumstance led to a significant decrease in the number of patients requiring additional oxygen support, which was 94% in the study group and 100% in the control group by the 7th day, and 16% in the study group and 44% in the control group by the 14th day. In particular, the number of patients requiring high-flow oxygen therapy in the study group decreased from 34% on the 5th day to 2% on the 14th day, while in the control group over the same period there was a decrease from 60% to 32%. When analyzing the volumetric oxygen consumption in the study group, even taking into account the oxygen consumption for hyperbaric oxygenation, a decrease in the average daily oxygen consumption was recorded from 13.9 L/min on the 5th day to 9.3 L/min on the 14th day, while in the control group for the same period from 17.2 L/min to 14.5 L/min. The length of stay of patients in the intensive care unit in the study group was 10 (8; 12) vs. 13 (11; 23) bed-days (p=0.002) in the control group, and the total length of hospitalization was 16 (13.3; 20) vs. 21 (19; 29) bed-days (p< 0.001) in the study and control groups, respectively.

DISCUSSION: The early inclusion of hyperbaric oxygen therapy in the complex therapy of patients with a new coronavirus infection led to a significant increase in the level of SpO2 starting from the 7th day. This circumstance led to a significant decrease in number of patients requiring additional oxygen support in the study group compared to the control. This, in turn, affected the reduction in volumetric oxygen consumption in the study group, even taking into account the oxygen consumption on hyperbaric oxygenation. In addition, in the study group, positive dynamics according to CT data, a more rapid decrease in the level of C-reactive protein, were more often recorded. All these observations indicate a more rapid normalization of the state of the body due to the elimination of hypoxia, a decrease in the inflammatory response and restoration of lung function in patients who underwent hyperbaric oxygen therapy.

CONCLUSION: The inclusion of HBO in the complex therapy of patients with a new coronavirus infection with severe lung damage (more than 50%) allows to stabilize the condition in a short time due to a more intensive decrease in the degree of lung damage according to CT data, early refusal of additional oxygen support, improvement of the psycho-emotional state, which in generally leads to a reduction in the length of stay of patients both in the ICU and in the hospital department.

About the authors

S. S. Petrikov

Sklifosovsky Research Institute for Emergency Medicine

Author for correspondence.
Email: fake@neicon.ru
ORCID iD: 0000-0003-3292-8789

Sergey S. Petrikov — Dr. of Sci. (Med.), Corresponding member of RAS, Director

129090, Moscow, Bolshaya Sukharevskaya sq., 3

Russian Federation

A. K. Evseev

Sklifosovsky Research Institute for Emergency Medicine

Email: EvseevAK@sklif.mos.ru
ORCID iD: 0000-0002-0832-3272

Anatoly K. Evseev — Dr. of Sci. (Chem.), Leading Researcher

129090, Moscow, Bolshaya Sukharevskaya sq., 3

Russian Federation

O. A. Levina

Sklifosovsky Research Institute for Emergency Medicine

Email: levina_olga@bk.ru
ORCID iD: 0000-0002-4811-0845

Olga A. Levina — Cand. Of Sci. (Med.), Leading Researcher

129090, Moscow, Bolshaya Sukharevskaya sq., 3

Russian Federation

A. K. Shabanov

Sklifosovsky Research Institute for Emergency Medicine

Email: aslan_s@mail.ru
ORCID iD: 0000-0002-3417-2682

Aslan K. Shabanov — Dr. of Sci. (Med.), Deputy Chief Physician

129090, Moscow, Bolshaya Sukharevskaya sq., 3

Russian Federation

I. V. Goroncharovskaya

Sklifosovsky Research Institute for Emergency Medicine

Email: goririna22@gmail.com
ORCID iD: 0000-0003-0113-306X

Irina V. Goroncharovskaya — Cand. of Sci. (Chem.), Senior  Researcher

129090, Moscow, Bolshaya Sukharevskaya sq., 3

Russian Federation

N. A. Potapova

Sklifosovsky Research Institute for Emergency Medicine

Email: PotapovaNA@sklif.mos.ru

Natalia A. Potapova — Anesthesiologist and Intensive Care Physician

129090, Moscow, Bolshaya Sukharevskaya sq., 3

Russian Federation

D. S. Slobodeniuk

Sklifosovsky Research Institute for Emergency Medicine

Email: fdashka@mail.ru

Daria S. Slobodeniuk — Anesthesiologist and Intensive Care Physician  

129090, Moscow, Bolshaya Sukharevskaya sq., 3

Russian Federation

A. A. Grin

Sklifosovsky Research Institute for Emergency Medicine

Email: aagreen@yandex.ru
ORCID iD: 0000-0003-3515-8329

Andrey A. Grin — Dr. of Sci. (Med.), Corresponding member 

129090, Moscow, Bolshaya Sukharevskaya sq., 3

Russian Federation

References

  1. Mokhtari T., Hassani F., Ghaffari N., Ebrahimi B., Yarahmadi A., Hassanzadeh G. COVID-19 and multiorgan failure: A narrative review on potential mechanisms // J. Mol. Histol. 2020. Vol. 51, Nо. 6. P. 613–628. doi: 10.1007/s10735-020-09915-3.
  2. Zaim S., Chong J.H., Sankaranarayanan V., Harky A. COVID-19 and Multiorgan Response // Curr. Probl. Cardiol. 2020. Vol. 45, Nо. 8. Article 100618. doi: 10.1016/j.cpcardiol.2020.100618.
  3. Desai A.D., Lavelle M., Boursiquot B.C., Wan E.Y. Long-term complications of COVID-19 // Am. J. Physiol. Cell Physiol. 2022. Vol. 322, Nо. 1. P. C1–C11. doi: 10.1152/ajpcell.00375.2021.
  4. Long B., Brady W.J., Koyfman A., Gottlieb M. Cardiovascular complications in COVID-19 // Am. J. Emerg. Med. 2020. Vol. 38, Nо. 7. P. 1504–1507. PMID: 32317203. doi: 10.1016/j.ajem.2020.04.048.
  5. Liu D., Wang Q., Zhang H., Cui L., Shen F., Chen Y., Sun J., Gan L., Sun J., Wang J., Zhang J., Cai Q., Deng J., Jiang J., Zeng L. Viral sepsis is a complication in patients with Novel Corona Virus Disease (COVID-19) // Med. Drug Discov. 2020. Vol. 8. Article 100057. doi: 10.1016/j.medidd.2020.100057.
  6. Da Silva Ramos F.J., de Freitas F.G.R., Machado F.R. Sepsis in patients hospitalized with coronavirus disease 2019: how often and how severe? // Curr. Opin. Crit. Care. 2021. Vol. 27, Nо. 5. P. 474–479. doi: 10.1097/MCC.0000000000000861.
  7. Laveneziana P., Sesé L., Gille T. Pathophysiology of pulmonary function anomalies in COVID-19 survivors // Breathe. 2021. Vol. 17, Nо. 3. Article 210065. doi: 10.1183/20734735.0065–2021.
  8. Hussain M., Syed S.K., Fatima M., Shaukat S., Saadullah M., Alqahtani A.M., Alqahtani T., Emran T.B., Alamri A.H., Barkat M.Q., Wu X. Acute respiratory distress syndrome and COVID-19: A literature review // J. Inflam. Res. 2021. Vol. 14. P. 7225–7242. doi: 10.2147/JIR.S334043.
  9. Saeed G.A., Gaba W., Shah A., Helali A.A.A., Raidullah E., 2 Ali A.B.A., Elghazali M., Ahmed D.Y., Kaabi S.G.A., Almazrouei S. Correlation between chest CT severity scores and the clinical parameters of adult patients with COVID-19 pneumonia // Radiol. Res. Pract. 2021. Vol. 2021. Article 6697677. doi: 10.1155/2021/6697677.
  10. Lei Q., Li G., Ma X., Tian J., Wu Y.F., Chen H., Xu W., Li C., Jiang G. Correlation between CT findings and outcomes in 46 patients with coronavirus disease // Sci. Rep. 2019. Vol. 11. Article 1103. doi: 10.1038/s41598-020-79183-4.
  11. Galeeva J., Babenko V., Bakhtyev R., Baklaushev V., Balykova L., Bashkirov P., Bespyatykh J., Blagonravova A., Boldyreva D., Fedorov D., Gafurov I., Gaifullina R., Galova E., Gospodaryk A., Ilina E., Ivanov K., Kharlampieva D., Khromova P., Klimina K., Kolontarev K., Kolyshkina N., Koritsky A., Kuropatkin V., Lazarev V., Manolov A., Manuvera V., Matyushkina D., Morozov M., Moskaleva E., Musarova V., Ogarkov O., Orlova E., Pavlenko A., Petrova A., Pozhenko N., Pushkar D., Rumyantsev A., Rumyantsev S., Rumyantsev V., Rychkova L., Samoilov A., Shirokova I., Sinkov V., Solovieva S., Starikova E., Tikhonova P., Trifonova G., Troitsky A., Tulichev A., Udalov Yu., Varizhuk A., Vasiliev A., Veselovsky V., Vereshchagin R., Volnukhin A., Yusubalieva G., Govorun V. 16S rRNA gene sequencing data of the upper respiratory tract microbiome in the SARS-CoV-2 infected patients // Data Br. 2022. Vol. 40. Article 107770. doi: 10.1016/j.dib.2021.107770.
  12. Babenko V., Bakhtyev R., Baklaushev V., Balykova L., Bashkirov P., Bespyatykh J., Blagonravova A., Boldyreva D., Fedorov D., Gafurov I., Gaifullina R., Galeeva J., Galova E., Gospodaryk A., Ilina E., Ivanov K., Kharlampieva D., Khromova P., Klimina K., Kolontarev K., Kolyshkina N., Koritsky A., Kuropatkin V., Lazarev V., Manolov A., Manuvera V., Matyushkina D., Morozov M., Moskaleva E., Musarova V., Ogarkov O., Orlova E., Pavlenko A., Petrova A., Pozhenko N., Pushkar D., Rumyantsev A., Rumyantsev S., Rumyantsev V., Rychkova L., Samoilov A., Shirokova I., Sinkov V., Solovieva S., Starikova E., Tikhonova P., Trifonova G., Troitsky A., Tulichev A., Udalov Y., Varizhuk A., Vasiliev A., Vereshchagin R., Veselovsky V., Volnukhin A., Yusubalieva G., Govorun V. Analysis of the upper respiratory tract microbiota in mild and severe COVID-19 patients // bioRxiv 2021.09.20.461025. doi: 10.1101/2021.09.20.461025.
  13. Цыганков К.А., Грачев И.Н., Шаталов В.И., Щеголев А.В., Аверьянов Д.А., Лакотко Р.С., Карнаушкина М.А. Влияние неинвазивных методик респираторной поддержки на частоту летального исхода у взрослых пациентов с тяжелой дыхательной недостаточностью, вызванной новой коронавирусной инфекцией // Вестник анестезиологии и реаниматологии. 2021. Т. 18, № 1. С. 47–56.
  14. Авдеев С.Н. Неинвазивная вентиляция легких при новой коронавирусной инфекции COVID-19 // Пульмонология. 2020. Т. 30, № 5. С. 679–687.
  15. Winck J.C., Scala R. Non-invasive respiratory support paths in hospitalized patients with COVID-19: proposal of an algorithm // Pulmonology. 2021. Vol. 27, Nо. 4. P. 305–312. doi: 10.1016/j.pulmoe.2020.12.005.
  16. Cai S., Zhu F., Hu H., Xiang H., Wang D., Wang J., Li L., Yang X., Qin A., Rao X., Luo Y., Li J., Kashani K.B., Hu B., Peng Z. Assessment of respiratory support decision and the outcome of invasive mechanical ventilation in severe COVID-19 with ARDS // J. Intensive Med. 2022. doi: 10.1016/j.jointm.2021.12.003.
  17. Wunsch H. Mechanical Ventilation in COVID-19: Interpreting the Current Epidemiology // Am. J. Respir. Crit. Care Med. 2020. Vol. 202, Nо. 1. P. 1–4. doi: 10.1164/rccm.202004-1385ED
  18. Petrikov S.S., Evseev A.K., Levina O.A., Shabanov A.K., Kulabukhov V.V., Kutrovskaya N.Yu., Borovkova N.V., Klychnikova Е.V., Goroncharovskaya I.V., Tazina E.V., Popugaev K.А., Kosolapov D.A., Slobodeniuk D.S. Hyperbaric oxygen therapy in patients with COVID-19 // General Reanimatology. 2020. Vol. 16, Nо. 6. P. 4–18. doi: 10.15360/1813-9779-2020-6-4-18.
  19. Bertini P., Guarracino F., Falcone M., Nardelli P., Landoni G., Nocci M., Paternoster G. ECMO in COVID-19 patients: A systematic review and meta-analysis // J. Cardiothorac. Vasc. Anesth. 2021. In Press. doi: 10.1053/j.jvca.2021.11.006.
  20. Badulak J., Antonini M.V., Stead C.M., Shekerdemian L., Raman L., Paden M.L., Agerstrand C., Bartlett R.H., Barrett N., Combes A., Lorusso R., Mueller T., Ogino M.T., Peek G., Pellegrino V., Rabie A.A., Salazar L., Schmidt M., Shekar K., MacLaren G., Brodie D. Extracorporeal Membrane Oxygenation for COVID-19: Updated 2021 Guidelines from the Extracorporeal Life Support Organization // ASAIO Journal. 2021. Vol. 67, Nо. 5. P. 485–495. doi: 10.1097/MAT.0000000000001422.
  21. Zhong X., Tao X., Tang Y., Chen R. The outcomes of hyperbaric oxygen therapy to retrieve hypoxemia of severe novel coronavirus pneumonia: first case report // Chin. J. Naut. Med. Hyperbaric Med. 2020. Vol. 27. P. E001-E001. doi: 10.3760/cma.j.issn.1009-6906.2020.0001.e.
  22. Самойлов А.С., Удалов Ю.Д., Шеянов М.В., Жолинский А.В., Литвиненко А.Б. Опыт применения гипербарической оксигенотерапии с использованием портативных барокамер для лечения пациентов с новой коронавирусной инфекцией COVID-19 // Биомедицина. 2020.
  23. Guo D., Pan S., Wang M.M., Guo Y. Hyperbaric oxygen therapy may be effective to improve hypoxemia in patients with severe COVID-2019 pneumonia: two case reports // Undersea Hyperbaric Medicine. 2020. Vol. 47, Nо. 2. P. 181–187.
  24. Thibodeaux K., Speyrer Z., Raza A., Yaakov R., Serena T.E. Hyperbaric oxygen therapy in preventing mechanical ventilation in COVID-19 patients: a retrospective case series // J. Wound Care. 2020. Vol. 29, Sup. 5a. P. S4–S8. doi: 10.12968/jowc.2020.29.Sup5a.S4.
  25. Gorenstein S.A., Castellano M.L., Slone E.S., Gillette B., Liu H., Alsamarraie C., Jacobson A.M., Wall S.P., Adhikari S., Swartz J.L., McMullen J.J.S., Osorio M., Koziatek C.A., Lee D.C. Hyperbaric oxygen therapy for COVID-19 patients with respiratory distress: treated cases versus propensity-matched controls // Undersea Hyperbaric Medicine. 2020. Vol. 47, Nо. 3. P. 405–413.
  26. Левина О.А., Евсеев А.К., Шабанов А.К., Кулабухов В.В., Кутровская Н.Ю., Горончаровская И.В., Попугаев К.А., Косолапов Д.А., Слободенюк Д.С., Петриков С.С. Безопасность применения гипербарической оксигенации при лечении COVID-19 // Журнал им. Н. В. Склифосовского «Неотложная медицинская помощь». 2020. Т. 9, № 3. C. 314–320.
  27. Cannellotto M., Duarte M., Keller G., Larrea R., Cunto E., Chediack V., Mansur M., Daniela M Brito D.M., García E., Di Salvo H.E., Verdini F., Domínguez C., Jorda-Vargas L., Roberti J., Di Girolamo G., Estrada E. Hyperbaric oxygen as an adjuvant treatment for patients with COVID-19 severe hypoxaemia: a randomised controlled trial // Emerg. Med. J. 2022. Vol. 39, Nо. 2. P. 88–93. doi: 10.1136/emermed-2021-211253.
  28. Liang Y., Fan N., Zhong X., Fan W. A case report of a patient with severe type of coronavirus disease 2019 (COVID-19) treated by hyperbaric oxygen: CT dynamic changes // Iran. J. Radiol. 2020. Vol. 17, Nо. 4. Article e104475. doi: 10.5812/iranjradiol.104475.
  29. Левина О.А., Евсеев А.К., Шабанов А.К., Горончаровская И.В., Кулабухов В.В., Боровкова Н.В., Клычникова Е.В. Гипербарическая оксигенация в лечении пациентов с новой коронавирусной инфекцией COVID-19 // Диагностика и интенсивная терапия больных COVID-19: рук-во для врачей / под ред. С. С. Петрикова. М.: ГЭОТАР-Медиа, 2021. С. 393–410.
  30. Rossignol D.A., Rossignol L.W., James S.J., Melnyk S., Mumper E. The effects of hyperbaric oxygen therapy on oxidative stress, inflammation, and symptoms in children with autism: an open-label pilot study // BMC Pediatrics. 2007. Vol. 7, Article 36. doi: 10.1186/1471-2431-7-36.
  31. Chen C.Y., Wu R.W., Hsu M.C., Hsieh C.J., Chou C.M. Adjunctive hyperbaric oxygen therapy for healing of chronic diabetic foot ulcers // J. Wound Ostomy. Continence Nurs. 2017. Vol. 44, Nо. 6. P. 536–545. doi: 10.1097/WON.0000000000000374.
  32. Resanovic I., Gluvic Z., Zaric B., Sudar-Milovanovic E., Jovanovic A., Milacic D., Isakovic R., Isenovic E.R. Early effects of hyperbaric oxygen on inducible nitric oxide synthase activity/expression in lymphocytes of type 1 diabetes patients: A prospective pilot study // Int. J. Endocrinol. 2019. Vol. 2019. Article 2328505. doi: 10.1155/2019/2328505.
  33. Mulawarmanti D., Parisihni K., Widyastuti W. The impact of hyperbaric oxygen therapy on serum C-reactive protein levels, osteoprotegerin expression, and osteoclast numbers in induced-periodontitis diabetic rats // Eur. J. Dent. 2020. Vol. 14, Nо. 3. P. 404–409. doi: 10.1055/s-0040-1712072.
  34. Silke D. De Wolde S.D., Hulskes R.H., Weenink R.P., Hollmann M.W., Van Hulst R.A. The effects of hyperbaric oxygenation on oxidative stress, inflammation and angiogenesis // Biomolecules. 2021. Vol. 11, Nо. 8. Article 1210. doi: 10.3390/biom11081210.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c)


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies